<DOC>
	<DOCNO>NCT00795197</DOCNO>
	<brief_summary>A screening study identify characterize disease status patient Gaucher Type 1 disease potential inclusion subsequent phase 3 clinical study .</brief_summary>
	<brief_title>A Screening Study Evaluating Disease Status Gaucher Type I Patients</brief_title>
	<detailed_description>The primary objective screening study identify characterize disease status patient Gaucher Type 1 disease potential inclusion subsequent Phase 3 clinical study evaluate efficacy safety Genz-112638 . This multi-center , multi-national screening study assess disease status patient Gaucher Type 1 disease utilize criterion eligible enrollment subsequent phase 3 clinical study . The assessment perform study standard care evaluation symptom Gaucher Type 1 disease . No study drug administer screen study .</detailed_description>
	<mesh_term>Gaucher Disease</mesh_term>
	<criteria>The Patient ( parent/legal guardian ) willing able provide write informed consent . The patient follow manifestation Gaucher Type 1 disease identify prior screening : A. Splenomegaly , B. Hepatomegaly , C. Anemia /or thrombocytopenia . The patient 16 65 year age . For patient &lt; 18 year age , patient 's Tanner stage â‰¥ 4 . The patient partial splenectomy within 36 month prior screen total splenectomy . The patient receive miglustat within 3 month prior screen . The patient receive enzyme replacement therapy within 9 month prior screen . The patient know evidence neurologic ( e.g. , peripheral neuropathy , tremor , seizure , Parkinsonism , cognitive impairment ) pulmonary involvement ( e.g. , pulmonary hypertension ) relate Gaucher Type 1 disease . The patient know documentation new pathological bone involvement ( e.g. , osteonecrosis , pathological fracture , etc . ) bone crisis ( pain acute onset require immobilization affect area , narcotic relief pain , may accompany periostal elevation , increase white cell count , fever , immobility &gt; 3 day ) 12 month prior screen , determine investigator . The patient transfusion dependent . The patient ever radiation treatment . The patient know prior esophageal varix liver infarction . The patient know clinically significant disease , Gaucher Type 1 disease , include cardiovascular , renal , hepatic , gastrointestinal , pulmonary , neurologic , endocrine , metabolic , psychiatric disease , medical condition , serious intercurrent illness . The patient know following : Clinically significant family history ( sudden cardiac death 1st 2nd degree relative ) , cardiac medical history ( include myocardial infraction [ MI ] past year ) , cardiac assessments/symptoms consistent ischemia . The patient know following : Specific arrythmias find cardiac monitoring severe 1st degree atrioventricular ( AV ) block , 2nd 3rd degree AV block , highly frequent run ( 3 ) atrial premature contraction ( APC 's ) premature ventricular contraction ( PVC 's ) , complete leave right well partial leave bundle branch block , prolong QT interval . The patient previously test positive human immunodeficiency virus ( HIV ) antibody , Hepatitis C antibody , Hepatitis B surface antigen . The patient receive investigational product within 30 day prior screen . The patient history cancer , exception basal cell carcinoma . The patient pregnant lactating .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Gaucher Disease ,</keyword>
	<keyword>acid B-glucosidase ,</keyword>
	<keyword>gluco cerebrosidase ,</keyword>
	<keyword>glucosylceramide ,</keyword>
</DOC>